卡瑞利珠致反应性毛细血管增生症1例

1例55岁男性患者,因肝癌晚期伴腹腔转移,术后口服仑伐替尼(12 mg,qd),1个月后抗癌方案调整为仑伐替尼联合卡瑞利珠(200 mg,q 2 w,ivgtt),卡瑞利珠首次治疗后12 d,患者双脚及脚踝出现点状鲜红色圆形丘疹,诊断为反应性皮肤毛细血管增生症(RCCEP),遂自行停用仑伐替尼,后范围进一步扩大至腰背部...

A case of reactive cutaneous capillary endothelial proliferation caused by camrelizumab

A 55-year-old male patient took lenvatinib(12 mg,qd)after operation of advanced hepatocellular carcinoma with abdominal metastasis.1 month later,the therapeutic regimen changed to lenvatinib combined with camrelizumab(200 mg,q 2 w,ivgtt).On the 12th day of the first administraion of camrelizumab,he developed bright red round dot papules on both feet and ankles,which was diagnosed as reactive cutaneous capillary endothelial proliferation(RCCEP).Lenvatinib was discontinued by himself,and the papules further expanded to the lower back and oropharyngeal mucosa.The patient retook lenvatinib(12 mg,qd)advised by pharmacist and the symptoms of RCCEP improved significantly after 10 days.After about 10 days of the second administraion of camrelizumab,he developed papules on both feet again,which was less severe than the first time,and no rash was found at other parts.He was asked to avoid scratching papules and no special treatment was given to him.5 days later,the rash basically disappeared.RCCEP did not reoccurred during the course of subsequent treatment with camrelizumab.The patient was discharged from the hospital after remission.